文献速递呼吸道感染

病毒学抑制的HIV成人患者社区获得性肺炎链球菌肺炎:匹配病例对照研究

Community-Acquired Pneumococcal Pneumonia in Virologically Suppressed HIV-Infected Adult Patients: A Matched Case-Control Study.
PubMed 文献 · Chest · 2017-03-14

该匹配病例对照研究在西班牙巴塞罗那医院开展(2001-2016年),比较了50例病毒学抑制且CD4+ T细胞>350 cells/mm3的HIV感染患者与100例匹配对照者的肺炎链球菌肺炎临床特征与结局。结果显示两组在ICU入住率、机械通气需求、住院时长及30天死亡率方面均无显著差异,HIV感染者未表现出更严重的临床表现或更差预后。

要点

  • 病毒学抑制且CD4+>350的HIV患者肺炎链球菌肺炎严重程度与未感染者相当。
  • 两组ICU入住率、机械通气、住院时长及30天死亡率均无显著差异。
  • 此类HIV患者无需因HIV感染而改变治疗、入院或照护场所。

核心结论

  • 病毒学抑制且CD4+ T细胞>350 cells/mm3的HIV感染者因肺炎链球菌肺炎住院时,病情不更重且预后不更差。

研究设计与样本

  • 匹配病例对照研究,在西班牙巴塞罗那医院开展(2001-2016年),纳入50例HIV感染病例和100例非HIV对照。
  • 对照按年龄(±10岁)、性别、合并症及同一日历期间的肺炎诊断进行匹配。

主要发现

  • 病例组流感感染率14% vs 对照组2%(P = .007)。
  • 病例组肺炎链球菌疫苗接种率10% vs 对照组1%(P = .016)。
  • 病例组合并乙型肝炎病毒感染率6% vs 对照组0%(P = .036)。
  • 两组ICU入住率18% vs 27%(P = .22),机械通气需求12% vs 8%(P = .43)。
  • 两组住院时长均为7天(P = .76),30天死亡率均为0%。

临床怎么用

  • 对于病毒学抑制且CD4+ T细胞>350 cells/mm3的HIV感染者,肺炎链球菌肺炎的治疗、入院及照护场所无需区别于一般人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The study aimed to investigate whether the clinical presentations and outcomes (length of stay, ICU admission, and 30-day mortality) of pneumococcal pneumonia in virologically suppressed patients who were HIV-infected on ART with a CD4+ T-cell count > 350 cells/mm3 are comparable to those seen in patients with HIV, using a case-control design. METHODS: A case-control study was carried out in Hospital Clinic, Barcelona, Spain (2001-2016). Control patients were matched by age (±10 years), sex, comorbidities, and pneumonia diagnosis in the same calendar period. Clinical presentation and outcomes of pneumococcal pneumonia in patients who were and were not infected with HIV were compared. RESULTS: Pneumococcal pneumonia was studied in 50 cases (HIV infection) and 100 control patients (non-HIV infection). Compared with the control patients, case patients had higher rates of influenza (14% vs 2%, P = .007) and pneumococcal vaccination (10% vs 1%, P = .016). The group of cases also presented a higher rate of coinfection with hepatitis B virus (6% vs 0%, P = .036). Both groups presented similar ICU admission (18% vs 27%, P = .22), need for mechanical ventilation (12% vs 8%; P = .43), length of stay (7 days vs 7 days, P = .76), and 0% of 30-day mortality. No evidence was found of a more severe presentation or a worse clinical outcome in cases than in control patients. CONCLUSIONS: Pneumococcal pneumonia episodes requiring hospitalization in virologically suppressed patients with HIV with > 350 CD4+ T-cell count/mm3 were neither more severe nor had worse prognosis compared with uninfected patients. These results support the fact that such patients do not need treatment, admission, or care sites different to the general population. TRIAL REGISTRY: ClinicalTrials.gov; No. 2009/5451; URL: www.clinicaltrials.gov.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Cillóniz C, Torres A, Manzardo C, et al. Community-Acquired Pneumococcal Pneumonia in Virologically Suppressed HIV-Infected Adult Patients: A Matched Case-Control Study. Chest. 2017. PMID: 28302496. doi:10.1016/j.chest.2017.03.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。